2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1691

The Comparative Immunogenicity of Biologic Therapy and Its Clinical Relevance in Psoriatic Arthritis: A Systematic Review of the Literature
Abstract Number: 1564

The Comprehensive Analysis for the Transcriptional Organization of Stimuli Responses in Fibroblast-like Synoviocytes from Rheumatoid Arthritis Patients
Abstract Number: 1879

The Correlation Between Oxidized Low-Density Lipoprotein and Clinical Manifestations in Patients with Systemic Sclerosis
Abstract Number: 1223

The Cost of Confronting Osteoporosis:Cost Study of a Fracture Liaison Service
Abstract Number: 1081

The CRL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Inhibits BAFF-Mediated Plasmablast Differentiation and Immunoglobulin Secretion from Class Switched CD27+IgD- Memory and Lupus-Associated CD27-IgD- Double Negative B-Cells
Abstract Number: 2365

The Cross-Sectional and Longitudinal Associations Between Metabolic Syndrome and Hand Osteoarthritis – Data from the Framingham Study
Abstract Number: 532

The DAS28 Score May Misread Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 3207

The Deficiency of Adenosine Deaminase Type 2 (DADA2)—Results of Anti-TNF Treatment in a Cohort of Patients with a History of Stroke
Abstract Number: 2407

The Descriptive Epidemiology of Acute Rheumatic Fever and Post-Streptococcal Reactive Arthritis in Japan
Abstract Number: 1607

The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Abstract Number: 1165

The Development of an Interdisciplinary Treatment Program for Fibromyalgia in a Tertiary Medical Center Focused upon Rheumatology and Internal Medicine
Abstract Number: 3151

The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies in RA Patients Starting Methotrexate Treatment
Abstract Number: 711

The Diagnostic Value of the Symptom of Inflammatory Back Pain in the Rheumatology Setting
Abstract Number: 2376

The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review
Abstract Number: 854

The Ducas: Proposal for a Digital Ulcer Assessment Score in Scleroderma

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].